Healthcare provider profile · identity verified

Bobby Abraham, MD

Internal Medicine · ROCKLEDGE, FL · NPI 1780606541

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	198	51
Rosuvastatin Calcium	Rosuvastatin Calcium	152	48
Amlodipine Besylate	Amlodipine Besylate	127	35
Metformin Hcl	Metformin Hcl	123	39
Lisinopril	Lisinopril	121	37
Glimepiride	Glimepiride	106	33
Alprazolam	Alprazolam	101	25
Atorvastatin Calcium	Atorvastatin Calcium	100	29
Losartan Potassium	Losartan Potassium	90	30
Metoprolol Succinate	Metoprolol Succinate	90	26
Simvastatin	Simvastatin	80	21
Cephalexin	Cephalexin	77	47
Tamsulosin Hcl	Tamsulosin Hcl	74	17
Temazepam	Temazepam	71	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	67	17
Pantoprazole Sodium	Pantoprazole Sodium	60	20
Furosemide	Furosemide	57	21
Omeprazole	Omeprazole	57	21
Methylprednisolone	Methylprednisolone	55	38
Gabapentin	Gabapentin	54	15
Zolpidem Tartrate	Zolpidem Tartrate	53	11
Carvedilol	Carvedilol	47	14
Clopidogrel	Clopidogrel Bisulfate	45	14
Allopurinol	Allopurinol	44	12
Valsartan	Valsartan	40	12
Albuterol Sulfate Hfa	Albuterol Sulfate	39	15
Hydrochlorothiazide	Hydrochlorothiazide	39	12
Potassium Chloride	Potassium Chloride	37	11
Pravastatin Sodium	Pravastatin Sodium	34	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	33	26
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	33	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	30	suppressed
Duloxetine Hcl	Duloxetine Hcl	29	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	29	suppressed
Symbicort	Budesonide/Formoterol Fumarate	28	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	27	22
Famotidine	Famotidine	27	suppressed
Ventolin Hfa	Albuterol Sulfate	27	suppressed
Lorazepam	Lorazepam	25	suppressed
Tramadol Hcl	Tramadol Hcl	24	suppressed
Eliquis	Apixaban	22	suppressed
Mounjaro	Tirzepatide	22	suppressed
Warfarin Sodium	Warfarin Sodium	22	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	20	suppressed
Mupirocin	Mupirocin	20	suppressed
Synthroid	Levothyroxine Sodium	20	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	19	suppressed
Metolazone	Metolazone	19	suppressed
Verapamil Er	Verapamil Hcl	19	suppressed
Hydralazine Hcl	Hydralazine Hcl	18	suppressed
Ozempic	Semaglutide	18	suppressed
Levofloxacin	Levofloxacin	17	11
Meclizine Hcl	Meclizine Hcl	17	suppressed
Methocarbamol	Methocarbamol	17	suppressed
Prednisone	Prednisone	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Finasteride	Finasteride	16	suppressed
Meloxicam	Meloxicam	16	suppressed
Sertraline Hcl	Sertraline Hcl	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Atenolol	Atenolol	14	suppressed
Eszopiclone	Eszopiclone	14	suppressed
Novolin N Flexpen	Insulin Nph Human Isophane	14	suppressed
Ondansetron Hcl	Ondansetron Hcl	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Propranolol Hcl Er	Propranolol Hcl	14	suppressed
Tresiba Flextouch U-200	Insulin Degludec	14	suppressed
Azithromycin	Azithromycin	13	12
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Fluticasone Propionate	Fluticasone Propionate	13	suppressed
Montelukast Sodium	Montelukast Sodium	13	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed
Tresiba Flextouch U-100	Insulin Degludec	11	suppressed
Trulicity	Dulaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error